Australia-based Dimerix Limited (ASX: DXB) has completed its fifth and final major territorial licensing transaction for its Phase III kidney disease candidate DMX-200, granting Everest Medicines (HKEX: 1952) exclusive rights across Greater China, South Korea, and six Southeast Asian markets for up to USD 340 million plus royalties. The deal closes out a systematic territory-by-territory licensing program that has now covered every major global market for the small molecule CCR2 antagonist, which is in a fully recruited pivotal Phase III trial for focal segmental glomerulosclerosis (FSGS) — a rare progressive kidney disease with no approved therapies in the licensed territories.
Dimerix will receive a USD 10 million upfront payment within 45 business days, up to USD 30 million in development and regulatory milestones, and up to USD 300 million in commercial milestones, with tiered royalties of 10%–15% on net sales. Across all five transactions — including prior deals with Advanz Pharma (October 2023), Taiba Rare (May 2024), Fuso Pharmaceutical Industries (January 2025), and Amicus Therapeutics, now BioMarin (May 2025) — Dimerix may be eligible for up to approximately AUD 1.9 billion in aggregate upfront and milestone payments, plus royalties.
Deal context
DMX-200 is a CCR2 antagonist administered on top of a stable angiotensin II receptor blocker (ARB), the standard of care for hypertension and kidney disease. The compound is described by Dimerix as targeting the inflammatory component of FSGS — specifically monocyte and macrophage activation — to produce renoprotective effects beyond ARB monotherapy alone. The Phase III ACTION3 trial has enrolled 333 adult patients across 21 countries, including sites in mainland China, Hong Kong, Taiwan, Thailand, and Malaysia. A pre-specified interim analysis in early 2024 showed DMX-200 outperforming placebo in reducing proteinuria, and an April 2026 blinded statistical review confirmed the trial remains greater than 90% powered for its primary endpoint. Eight independent data monitoring committee reviews have identified no safety concerns to date.
Everest will be responsible for regulatory submissions, dossier maintenance, and all commercialization costs in the licensed territories. Dimerix retains responsibility for funding and executing the global ACTION3 trial. A Joint Steering Committee will coordinate development and commercialization activities across the licensed geography.